GOLGA6L9 Inhibitors
GOLGA6L9 inhibitors represent a class of chemical compounds specifically designed to impede the function of the protein GOLGA6L9, which plays a role in cellular processes. The exact biological function of GOLGA6L9 remains somewhat elusive, but it is known to be implicated in the complex network of golgin subfamily proteins that are integral to Golgi apparatus structure and function. Inhibitors that target GOLGA6L9 are characterized by their ability to interfere with the protein's interactions or its involvement in cellular trafficking pathways. The Golgi apparatus is central to modifying, sorting, and packaging proteins and lipids for secretion or use within the cell, and GOLGA6L9 is believed to be involved in maintaining its integrity. Inhibitors in this class bind to GOLGA6L9 or modify its expression, directly leading to disruptions in Golgi-mediated processes. This disruption can affect various downstream processes, such as the transport of proteins to their intended cellular locations, which is critical for maintaining cellular homeostasis and function.
The inhibitors of GOLGA6L9 operate through several possible mechanisms, such as inhibiting the protein's ability to bind to other golgin proteins or altering its normal localization within the cell. By doing so, they exert a profound influence on the structural dynamics of the Golgi apparatus, which may lead to a cascade of effects on cellular signaling pathways and protein trafficking. This can result in a global alteration of cellular functions that are dependent on the Golgi's role in processing and routing molecular cargoes. The precise molecular interaction between GOLGA6L9 inhibitors and their target is a subject of ongoing research, aiming to elucidate the subtle ways in which these compounds impact the protein's activity. With a better understanding of the mechanisms by which GOLGA6L9 operates within the cell, inhibitors can be fine-tuned to exert more specific and controlled effects on the protein, offering insights into the fundamental cell biology underlying Golgi apparatus function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
A phosphoinositide 3-kinase (PI3K) inhibitor that can indirectly inhibit GOLGA6L9 by disrupting the PI3K pathway, which is involved in Golgi apparatus function. The inhibition of PI3K can lead to reduced trafficking to and from the Golgi, which consequently could impact GOLGA6L9's function related to Golgi dynamics. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
An inhibitor of ADP-ribosylation factor (ARF), which plays a role in the formation of the Golgi complex. By inhibiting ARF, Brefeldin A can disrupt Golgi assembly and function, potentially leading to the downregulation of GOLGA6L9's activity. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Specifically targets the Golgi-associated protein GRASP55, disrupting the Golgi architecture. This disruption can impair the function of GOLGA6L9 by altering Golgi structure and maintenance where GOLGA6L9 is localized. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A GTPase inhibitor that targets dynamin, preventing the scission of clathrin-coated vesicles from the Golgi. This could reduce GOLGA6L9 activity by affecting vesicle trafficking and Golgi network maintenance. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that disrupts the Golgi's pH gradient and cation homeostasis, which can indirectly inhibit GOLGA6L9 by altering the Golgi environment necessary for its proper function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule-depolymerizing agent that can affect trafficking to and from the Golgi complex, potentially decreasing GOLGA6L9 activity due to altered transport dynamics. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
An inhibitor of N-linked glycosylation, which can indirectly decrease GOLGA6L9 activity by disrupting protein folding and trafficking within the Golgi. | ||||||
Neomycin sulfate | 1405-10-3 | sc-3573 sc-3573A | 1 g 5 g | $27.00 $35.00 | 20 | |
Binds to phosphoinositides, interfering with their function. This can hinder the Golgi's role in sorting and transporting proteins, indirectly affecting GOLGA6L9 activity. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Disrupts actin polymerization, consequently affecting cytoskeleton organization and potentially altering Golgi function and, indirectly, GOLGA6L9 activity. | ||||||
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
By influencing the activity of certain signaling pathways, such as NF-kB, it can indirectly affect the function of the Golgi apparatus and thus GOLGA6L9. | ||||||